Nautilus Biotechnology, Inc. (NAUT) Financial Statements
Free cash flow over the same period: -$51.9M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
NAUTNautilus Biotechnology, Inc.Follow NAUT — free
—
Price chart with a free account
- Market cap
- 412.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 27 Oct, in 3 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|
| Research & development | 29.4 | 37.7 | 47.3 | 50.5 | 41.1 | 38.5 | |
| Pre-tax income | -50.3 | -57.9 | -63.7 | -70.8 | -59.0 | -56.5 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
| Net income | -50.3 | -57.9 | -63.7 | -70.8 | -59.0 | -56.5 | |
| Diluted EPS ($) | -0.60 | -0.46 | -0.51 | -0.56 | -0.47 | -0.45 | |
| Diluted shares (mn) | 84.5 | 124.6 | 124.9 | 125.4 | 126.3 | — |
USD millions · SEC XBRL
Nautilus Biotechnology, Inc. — questions
- What is Nautilus Biotechnology, Inc.'s net income?
- -$56.5M over the twelve months to 2026-06-30.
- What is Nautilus Biotechnology, Inc.'s free cash flow?
- -$51.9M over the twelve months to 2026-06-30.
- What are Nautilus Biotechnology, Inc.'s diluted earnings per share?
- $-0.45 over the twelve months to 2026-06-30.
Every figure on this page comes from Nautilus Biotechnology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.